Involves transaction of at least 0.5% of the listed shares of a company. What was Glaxosmithkline Pharmaceuticals Ltd share price previously? Glaxosmithkline Pharmaceuticals Ltd share price was up ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

Rapid7’s financial performance has been a mixed bag in recent quarters, with the company experiencing both challenges and opportunities. With revenue reaching $844.01 million in the last twelve months ...

Arbor Realty Trust reported distributable earnings of $0.40 per share for the fourth quarter of 2024, surpassing the consensus estimate of $0.36 but falling short of some analysts’ expectations. The ...

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market.

DelveInsight's "DARZALEX Market Size, Forecast, and Market Insight Report" highlights the details around DARZALEX, a human ...

Investing.com – Denmark stocks were higher after the close on Thursday, as gains in the Personal & Household Goods, Consumer Goods ...

A month has gone by since the last earnings report for Netflix (NASDAQ:NFLX). Shares have added about 18.5% in that time frame, ...

DARZALEX has significant market potential as a leading monoclonal antibody for multiple myeloma treatment. Its approval in various combinations for both newly diagnosed and relapsed/refractory ...

VITRAKVI has strong market potential as a first-in-class TRK inhibitor for patients with NTRK gene fusion-positive cancers, regardless of tumor type. The growing adoption of precision oncology ...